L.P. Ra Capital Management Buys Shares of PepGen Inc. $PEPG

Written by Podchat · Published · Updated

Editorial illustration for PepGen Inc. (PEPG)

Key Points

  • L.P. Ra Capital Management bought 34,000 shares of PepGen Inc. ($PEPG).
  • $PEPG last traded around $1.83.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

L.P. Ra Capital Management, insider at PepGen Inc. ($PEPG), bought 34,000 shares at an average price of $0. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

PepGen Inc. Stock Down 40.6%

Shares of PepGen Inc. ($PEPG) traded around $1.83 on Tuesday, down 40.6% for the day.

Last price$1.83
Market cap$207.09M
Forward P/E-2.88
Beta1.89
52-week low$1.17
52-week high$7.80
50-day MA$2.35
200-day MA$3.69
Current ratio13.36
Quick ratio13.02
Debt-to-equity0.13

PepGen Inc. Earnings

EPS (ttm)-$0.97
Revenue (ttm)—
Net margin0%
Return on equity-75.45%
Next earningsNov 11, 2026

Analysts Set New Price Targets

Average target$10.19
High target$20
Low target$2.50
Analysts covering8

About PepGen Inc.

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

ExchangeNasdaqGS
SectorHealthcare
IndustryBiotechnology
HeadquartersBoston, MA
CEODr. James G. McArthur Ph.D.
Employees57
Websitehttps://www.pepgen.com

Get PepGen Inc. alerts

New 13F filings, insider trades, and analyst moves on $PEPG, sent to your inbox. Free, and you can unsubscribe anytime.

Related Filing Alerts

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.